SOURCE: Solos Endoscopy, Inc.

April 21, 2008 08:31 ET

Solos Endoscopy, Inc. to Introduce a New Line of Disposable Instruments Into the Breast Endoscopy Market

BOSTON, MA--(Marketwire - April 21, 2008) - Solos Endoscopy, Inc. (PINKSHEETS: SLSY) is pleased to announce that the company will release for sale to the medical community its new line of "MammoView" disposable instrumentation. The introduction of disposable instruments will allow Solos to at least double the size of its potential customer base.

The "MammoView" line of disposable instruments will consist of eight individual devices sold in three sterile sets. This configuration will allow physicians and hospitals more flexibility in their purchasing decisions.

"We are extremely excited about the introduction of the 'MammoView' line of disposable instruments. Although Solos is a company that has traditionally manufactured reusable instruments, we are confident that we will become the largest provider of disposable instruments to the U.S. breast endoscopy market by the end of the third quarter of 2008," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Information